Ginkgo Bioworks Holdings, Inc.

DNAReported to SECin USCIK 0001830214Filings at SEC EDGAR

No score on this page, by design. Everything here is a fact from a public U.S. register: insider filings at the SEC (Form 4), lobbying filings under the Lobbying Disclosure Act, trades reported by members of Congress under the STOCK Act, and fund holdings in 13F filings. Our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.

This page is free to read, and it stops after 5 rows. Those are the 5 most recent Form 4 lines at this company, out of 21. Reading the whole list, and the full version of each filer's page, is part of the subscription. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

The most recent filings

Most recent filing first: every line of every Form 4 at this company that passed our review, the same lines as on the register. Reported is the day the filing reached the SEC, usually within two business days of the trade. Amounts are in U.S. dollars, as the form states them.

5 of 21
Form 4 lines at Ginkgo Bioworks Holdings, Inc., most recent filing first
Filed byTypeValueReportedFiled byValueTypeSharesReported
HENRY CHRISTIAN O—Open-market sell$35,4055,000 sharesSep 16, 2026HENRY CHRISTIAN O$35,405Sell · Sep 16Open-market sell5,000Sep 16, 2026
Coen Steven P.See remarksOption exercise—156 sharesAug 25, 2026Coen Steven P.See remarks—Exercise · Aug 25Option exercise156Aug 25, 2026
Coen Steven P.See remarksOption exercise—587 sharesAug 25, 2026Coen Steven P.See remarks—Exercise · Aug 25Option exercise587Aug 25, 2026
Coen Steven P.See remarksOpen-market sell$2,302330 sharesAug 25, 2026Coen Steven P.See remarks$2,302Sell · Aug 25Open-market sell330Aug 25, 2026
Coen Steven P.See remarksOption exercise—156 sharesAug 25, 2026Coen Steven P.See remarks—Exercise · Aug 25Option exercise156Aug 25, 2026